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Abstract: Human neural stem cells (NSCs) from the developing embryo or the subventricular zone of the adult brain can poten-
tially elicit brain repair after injury or disease, either via endogenous cell proliferation or by cell transplantation. Profound knowl-
edge of the diverse signals affecting these cells is, however, needed to realize their therapeutic potential. Glutamate and group I
metabotropic glutamate receptors (mGluRs) affect proliferation and survival of rodent NSCs both during embryonic and post-
natal development. To investigate the role of group I mGluRs (mGluR1 and mGluR5) on human NSCs, we differentiated an
immortalized, forebrain-derived stem cell line in the presence or absence of glutamate and with addition of either the group I
mGluR agonist DHPG or the selective antagonists, MPEP (mGluR5) and LY367385 (mGluR1). Characterization of differentiated
cells revealed that both mGluR1 and mGluR5 were present on the cells. Addition of glutamate to the growth medium signifi-
cantly increased cell proliferation and reduced cell death, resulting in increased cell numbers. In the presence of glutamate, selec-
tive activation of group I mGluRs reduced gliogenesis, whereas selective inhibition of group I mGluRs reduced neurogenesis.
Our results substantiate the importance of glutamate signalling in the regulation of human NSCs and may as such be applied to
promote proliferation and neuronal differentiation.
In the adult brain, multi-potent neural stem cells (NSCs) are
mainly found in the forebrain subventricular zone (SVZ) and
in the dentate gyrus of the hippocampus, where they continu-
ously proliferate and differentiate into neurons, astrocytes and
oligodendrocytes [1–3]. Human NSC lines are highly valuable
as a source of cells for differentiation studies and genetic
manipulations [4], and they can be maintained in long-term
culture in the presence of epidermal growth factor (EGF)
and basic fibroblast growth factor (b-FGF) [5–7]. In vivo and
in vitro studies have shown that stem cells can recapitulate
embryonic and adult tissue development and therefore can be
used for repair of injured or defective tissue [8–10].
Given that glutamate is the primary excitatory neurotrans-
mitter in the central nervous system (CNS), extensive research
has been focused on the importance of this particular neuro-
transmitter. Today, it is well accepted that glutamate plays an
important role in developmental synaptogenesis, plasticity,
learning and memory processes [11,12]. Other studies docu-
ment the importance of glutamate for proliferation, differentia-
tion and survival of both embryonic stem cells (ESCs) and
NSCs [13–15].
In the CNS, glutamate exerts its effects through two differ-
ent groups of glutamate receptors: the ionotropic glutamate
receptors (iGluRs) and the metabotropic glutamate receptors
(mGluRs). iGluRs are fast-acting ligand-gated ion channels
and control the flow of cations leading to depolarization of
neurons [16]. In contrast, mGluRs are slow acting and modu-
late the response of the iGluRs [12]. MGluRs are members of
the super family C of G-protein-coupled receptors (GPCRs)
through which they activate different signal transduction path-
ways [17]. They can be subdivided into three different groups
based on signal transduction pathways, sequence homology
and pharmacological properties. Group I (mGluR1,5) is posi-
tively coupled to phospholipase C (PLC), and group II
(mGluR2,3) and group III (mGluR4,6,7,8) are negatively cou-
pled to the adenylate cyclase (AC) [18–21]. Group I mGluRs
are mainly localized on the post-synaptic glutamatergic neuron
[22], where activation enhances post-synaptic glutamatergic
excitability via interactions with other post-synaptic processes
such as iGluRs and ion channels [23,24]. Group I mGluRs
activate a positive-feedback system that creates calcium oscil-
lations and prolonged neurotransmission [18,25,26]. mGluR
subtype expression has been detected during embryonic devel-
opment [27–30] and also demonstrated in cultured neural pro-
genitor cells [15,31–34]. Activation of mGluR3 and mGluR5
has been shown to support proliferation and survival of mouse
NSCs and ESCs [35,36]. Furthermore, activation of mGluR3
can inhibit astrocyte differentiation by maintaining an undiffer-
entiated, proliferative state of NSCs [14]. In addition, mGluR5
activation plays an important role in neuroblast proliferation in
the ventral telencephalon and in the regulation of human
hippocampal development [29,37]. mGluR1 is less well
described in the context of embryonic development and NSCs.
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Expression of mGluR1 has been detected during human prenatal
development and post-natally in cortical areas, but not in the
SVZ [30]. However, a study has demonstrated mGluR1 expres-
sion on neural progenitors from adult mouse SVZ and a nega-
tive effect of mGluR1 inhibition on their proliferation [31].
The aim of this study was to investigate the effects of gluta-
mate and group I mGluRs on proliferation, differentiation and
survival of human NSCs derived from the developing fore-
brain. We establish for the first time the presence of mGluR1
and mGluR5 on differentiating NSCs of human forebrain ori-
gin and prove a positive effect of glutamate on their prolifera-
tion, survival and neuronal differentiation.
Materials and Methods
Human neural stem cells. Collection of foetal tissue, cell isolation
and immortalization are described elsewhere [38]. Briefly, human
foetal tissue (striatum and adjacent SVZ; gestational week 10–10.5,
crown-rump length 30 mm) was donated for research after written
informed consent was obtained from the women seeking abortion.
Tissue procurement was performed in accordance with the Declaration
of Helsinki and in agreement with the ethical guidelines of the
Network of European CNS Transplantation and Restoration
(NECTAR). Approval to use these tissues for research was granted by
the Lund University Hospital Ethical Committee, and their use was in
compliance with Spanish law 35/1988 on Assisted Reproduction.
Immortalization of telencephalic cells was carried out by infection
with a retroviral vector (LTR-vmyc-SV40p-Neo-LTR; replication
defective) coding for v-myc, a p100 gag-myc fusion protein isolated
from the avian virus genome. The resulting human neural stem cell
line (hNS1) divides approximately every 40 hr and have proven to be
stable even after long-term culturing (4 years; stable telomerase activ-
ity) [38].
hNS1 cells were stored at 80°C in 1-ml Eppendorf tubes with
0.5 ml HNSC100 medium (see below) containing pen-strep (Gibco
Invitrogen, Taastrup, Denmark), 10% bovine serum albumin (BSA,
Sigma Brøndby, Denmark) and 10% dimethyl sulfoxide (DMSO,
Sigma Brøndby, Denmark).
Maintenance and passaging of stem cells. Cells were thawed in 37°C
water, centrifuged at 130 9 g (5 min.; 4°C), resuspended in culture
medium and counted using a B€urker-T€urk counting chamber.
Propagation of cells took place in poly L-lysine (PLL, 10 lg/ml;
Sigma)-coated culture flasks (Nunc T-25) containing 15 ml HNSC100
medium (DMEM/F12 w. Glutamax (Gibco), 2% (v/v) 30% glucose
(Sigma), 0.5% (v/v) 1M Hepes (Gibco), 2.5% (v/v) AlbuMAX-I
(Gibco), 1% (v/v) N2 supplement (Gibco), 1% (v/v) NEAA (Sigma)
and 1% penicillin/streptomycin (Gibco) supplemented with 20 ng/ml
EGF (R&D Systems Oxon, UK) and 20 ng/ml bFGF (R&D Systems)
at 36°C in controlled atmospheric condition of 5% CO2 and 95%
humidified air. Medium was changed every 4 days, and cells passaged
at 70% confluence.
For cell passaging, medium was removed, adherent cells washed with
phosphate-buffered saline without calcium and magnesium (D-PBS; pH
7.4; Gibco) and cells detached by trypsin-EDTA (Gibco) diluted 1:10 in
D-PBS for 5 min. at 36°C. Trypsinized cells were separated using a ster-
ile Pasteur pipette, and the resulting cell suspension centrifuged for
5 min. at 4°C at 130 9 g. The supernatant was removed, and the cells
counted and resuspended in new T75 culture flasks.
Differentiation of stem cells. To investigate the effect of glutamate on
differentiation of hNS1 cells, standard serum-free synthetic medium
(HNSC100 medium, see above) containing L-glutamate (4 lM,
Sigma) or medium without glutamate was used.
The group I mGluR agonist (S)-3,5-dihydroxyphenylglycine
(DHPG; 10 lM, Tocris R&D Systems, Oxon, UK), the selective
mGluR1a antagonist (S)-(+)-a-amino-4-carboxy-2-methylbenzeneacetic
acid (LY367385; 10 lM, Tocris) or the selective mGluR5 antagonist
2-methyl-6-(phenylethynyl)pyridine hydrochloride (MPEP; 1 lM, To-
cris) was added to the medium with and without glutamate as
described in the following to investigate the influence of group I
mGluRs on differentiation of hNS1 cells. Previous work has proven
that such low doses of glutamate or DHPG are not excitotoxic
[39,40].
For differentiation, 20,000 cells/well were seeded into PLL-coated
24-well plates (Costar) with 0.5 ml hNS1 medium/well – with or with-
out glutamate and the group I mGluR ligands mentioned above
(n = 12–24/condition; 4 independent experiments). Cultures were
grown for 12 days in vitro (DIV), and the medium was changed every
fourth day. Samples for analysis of lactate dehydrogenase (LDH) were
collected at days 4 and 12 (see below).
Cell fixation and immunocytochemistry. Cells were fixed in 4%
paraformaldehyde in 0.15 M phosphate buffer, pH 7.4, for 20 min. and
then rinsed for 3 9 15 min. with 0.05 M Tris buffered saline (TBS, pH
7.4)/0.1% Triton X-100 (Sigma). Cultures were then pre-incubated for
30 min. in 0.05 M TBS/10% FBS (Gibco) before incubation with one
of the following primary antibodies in 0.05 M TBS/10% FBS for 24 hr
at 4°C: human nuclei (HN) 1:2000 (monoclonal mouse; Chemicon
Millipore, Hellerup, Denmark), b-tubulin III (b-tub III) 1:1000
(monoclonal mouse; Sigma), glial fibrillary acidic protein (GFAP)
1:5000 (polyclonal rabbit; DAKO Glostrup, Denmark) and Ki67 1:800
(polyclonal rabbit; Abcam Cambridge, UK). Control staining was
performed by excluding primary antibodies or using IgG rabbit 1:20,000
(DAKO) and IgG mouse 1:200 (DAKO). Non-bound antibody was
washed off by rinsing for 3 9 15 min. in TBS/0.1% Triton-X-100. The
cells were then incubated for 1 hr with one of the following biotinylated
secondary antibodies in 0.05 M TBS/10% FBS: anti-mouse antibody
1:200 (Amersham VWR-Bie and Berntsen, Denmark) and anti-rabbit
antibody 1:200 (Amersham VWR-Bie and Berntsen, Denmark). Cells
were washed for 3 9 15 min. with TBS/0.1% Triton X-100 and
incubated for 1 hr in horse radish peroxidase (HRP)-conjugated
streptavidin (DAKO) diluted 1:200 in 0.05 M TBS/10% FBS, then
rinsed for 15 min. in TBS before visualization of the
immunocytochemical complexes with 50 mg 3,30-diaminobenzidine
(DAB; Sigma) and 33 ll hydrogen peroxide, H2O2, per 100 ml TBS for
15 min. After rinsing for 15 min. with TBS and briefly with distilled
water, cultures were cover-slipped with Aquatex (MerckVWR-Bie and
Berntsen, Denmark). Photos of the stainings were taken using a bright
field microscope attached to a Leica DC camera Ballerup, Denmark.
Double immunofluorescence staining. Double immunofluorescence
staining was made using primary antibodies: anti-b-tub III 1:1000
(monoclonal mouse; Sigma), anti-mGluR1 1:500 (polyclonal rabbit;
Upstate)/anti-mGluR5 1:500 (monoclonal rabbit; R&D systems), anti-
GFAP-CY3 1:800 (monoclonal mouse; Sigma), anti-mGluR1/anti-
mGluR5, anti-HN 1:2000 (monoclonal mouse; Chemicon) and anti-
mGluR1/anti-mGluR5 to visualize the localization of group I mGluRs
on differentiated hNS1 cells. The cells were rinsed for 3 9 15 min.
with TBS/0.1% Triton-X-100. Non-specific binding sites were blocked
by incubation with TBS containing 5% goat serum for 30 min. The
cells were then incubated for 48 hr at 4°C with primary antibodies
(see above) diluted in 5% goat serum in TBS. Non-bound antibody
was washed out by rinsing for 3 9 15 min. with TBS/0.1% Triton-X-
100 followed by incubation for 2 hr with the following fluorophore-
conjugated secondary antibodies: anti-rabbit Alexa Fluor 488 1:200
(Invitrogen) and anti-mouse Alexa Fluor 555 1:200 (Invitrogen)
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diluted in 5% goat serum in TBS, no light to preserve fluorescence.
Excess non-bound antibody was washed off by rinsing for
3 9 15 min. with TBS and briefly with distilled water. Cells were
cover-slipped with Fluoromount (DAKO). Omission of the primary
or secondary antibody served as negative controls. Images were
recorded using a Zeiss photomicroscope, with an Alexa 488 and a
CY3 filter kit, attached to a Leica DC camera (Leica Microsystems).
Cell counting. Quantification of cells was performed using bright
field microscopy (Olympus Ballerup, Denmark). Numbers of Ki67-
positive cells, HN-positive cells, b-tub III-positive cells and GFAP-
positive cells were calculated based on analysis of six randomly
selected areas per well. Cell counting was performed using an ocular
counting grid with 100 equally sized squares at 9100 magnification
(Olympus; counting area, 1 mm2), guided by pre-defined fix points in
a computer-designed grid placed underneath the culture trays. Only
cells displaying an intense immunostaining, well-preserved cellular
structure and a distinct nucleus were counted. All cell counts were
performed by experimenter blind to sample identity.
Lactate dehydrogenase assay. As a measure of cell death, the content
of released LDH was determined at 4 and 12 days in vitro sing 90-ll
medium samples. 10 ll of Tris/NaCl buffer (0.813M Tris, 2.033M
NaCl; pH 7.2) was added to each sample, and samples were stored at
20°C until analysis. The rate of conversion of NADH to NAD+ as
an indicator of LDH activity was measured by a fully automatic
spectrophotometer (Cobas Mira, Hoffmann LaRoche). 20 ll pyruvate
and 240 ll NADH (both Sigma) were added to each 20 ll media
sample. The absorbance at 340 nm (37°C) was used as an index of
NADH concentration. Before each set of measurements, changes in
absorbance of LDH standard solutions (Boehringer Mannheim) were
measured for calculation of a standard curve.
Statistical analysis. Statistical comparisons were performed using
Instat, Graph Pad software (www.graphpad.com). The number of
Ki67-positive cells, HN-positive cells, b-tub III-positive cells and
GFAP-positive cells in the different experimental groups was
compared by one-way analysis of variance (ANOVA) followed by the
Bonferroni test. All values in text and graphs are presented as mean 
standard error of mean (SEM).
Results
Expression of group I metabotropic glutamate receptors.
To establish the presence of group I mGluRs on our human
NSCs (hNS1 cells) after in vitro differentiation, we performed
double immunocytochemistry using antibodies against
mGluR1/mGluR5 and the pan-neuronal marker b-tubulin III
(b-tub III) or the astroglial marker glial fibrillary acidic protein
(GFAP). A distinct co-existence of both receptor types was
detected on both b-tub III-positive neurons and GFAP-positive
astrocytes (fig. 1C, F, I and L).
Effect of glutamate on hNS1 cells.
To investigate the effects of glutamate in standard growth
medium (see Materials and Methods), we differentiated hNS1
cells in standard medium versus glutamate-free medium. When
grown in standard glutamate-containing medium, a significant
increase in the numbers of human nuclei (HN)-positive cells
(total cells) (fig. 2A,D) and Ki-67-positive proliferative cells
(fig. 2B,D) was seen. To investigate whether the increased
number of HN-positive cells was due to enhanced proliferation
exclusively, LDH measurements were performed in samples
of conditioned culture medium collected at days 4 and 12
in vitro. At both time-points, significantly less LDH was
detected for cultures grown in glutamate-containing medium,
compared to cultures grown in medium without glutamate sup-
plements (fig. 2C), suggesting less cell death in cultures
exposed to low-dose glutamate.
Phenotypic characterization of the cultures showed that cells
differentiated for 12 days in standard growth medium (4 lM
glutamate) contained significantly (1.3-fold; p < 0.05) more b-
tub III-positive neurons than cells grown in glutamate-free cul-
ture medium. Analysis of GFAP-positive cells revealed a non-
significant (1.1-fold; p > 0.05) tendency for more astroglia.
Effect of glutamate and group I mGluRs on stem cell
differentiation.
To eliminate the possibility that low doses of glutamate present in
standard cell culture medium would activate other glutamate recep-
tor subtypes than group I mGluRs, further cell differentiation exper-
iments were performed using both standard medium (low-dose
glutamate) and glutamate-free medium. Cells were differentiated in
the presence or absence of the group I mGluR agonist DHPG or the
selective antagonists LY367385 (mGluR1) or MPEP (mGluR5). In
glutamate-containing medium, activation of group I mGluRs with
DHPG significantly reduced the number of GFAP-positive astrogli-
al cells, whereas no significant change was detected for b-tub III-
positive neuronal cells. In contrast, selective inhibition of mGluR1
(LY367385) or mGluR5 (MPEP) significantly reduced the number
of b-tubulin III-positive cells (fig. 3A,B) but had no significant
effect on GFAP-positive cells (fig. 3C,D).
When glutamate was omitted from the growth medium, we
found no effect of DHPG-mediated group I mGluR activation
on either b-tub III-positive cells (fig. 4A,B) or GFAP-positive
cells (fig. 4C,D). When adding the selective antagonists
LY367385 or MPEP to the cells, only a non-significant ten-
dency for reduced number of b-tub III-positive cells was seen
(fig. 4A). In addition, no effect of LY367385 and MPEP on
numbers of GFAP-positive astroglial cells was found.
Discussion
Over the recent years, in vivo studies have characterized the
expression of mGluRs in the developing brains of rats and
mice, where group I mGluRs (mGluR1 and mGluR5) are dif-
ferentially regulated [22,27,28]. Moreover, cultured mouse
forebrain precursor cells have been reported to express func-
tional mGluR3 (group II mGluR subtype) and mGluR5 [32].
In rats, the level of mGluR1 expression increases post-natally
[41], whilst mGluR5 expression increases perinatally with the
highest expression level around second post-natal week, before
decreasing to adult levels [23,42,43]. mGluR5 has been found
in neurogenic zones, such as the rat external granule layer
(EGL) of the cerebellar cortex and in the SVZs [32].
Similar results have been shown for differentiating mouse
neural precursor cells, where mGluR5 is present at the highest
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level around day 1–3 and then gradually decreases [33].
mGluR5 is also expressed in astrocytes and oligodendroglial
progenitor cells [15,44].
During human prenatal development, mGluR5 expression
can be detected in cortical areas from gestational week 9 and
possibly earlier on, with strong expression in the ventricular/
SVZ. mGluR1 has been observed in the cortical plate from
gestational week 13, persisting throughout prenatal develop-
ment [30]. A recent study has shown mGluR5 to be present
prenatally in the human hippocampus on NSCs, neuroblasts
and mature neurons [29].
In this study, we report that differentiating NSCs, derived
from the human forebrain SVZ, express both mGluR1
and mGluR5. We also provide evidence that regulation of
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Fig. 1. Double immunofluorescence staining of differentiating forebrain-derived human neural stem cells (NSCs). To establish the presence of
group I metabotropic glutamate receptors (mGluRs), human NSCs were differentiated for 12 days in standard cell culture medium without mito-
gens. Combined immunofluorescence staining for the neuronal marker b-tubulin III (A) and mGluR1a (B) revealed a significant co-localization of
these markers (C). Similarly, b-tubulin III (D) and mGluR5 (E) were co-expressed in the cells (F). Also double immunofluorescence staining for
the astroglial marker GFAP (G) and mGluR1a (H) showed co-localization (I). In addition, GFAP (J) and mGluR5 (K) were co-expressed in some
cells (L). Scale bar = 50 lm.
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glutamate signalling may serve as a tool to promote prolifera-
tion and neuronal differentiation of human NSCs.
Exposure to low-dose glutamate stimulates cell proliferation
and reduces cell death.
It has previously been reported that exposure to low-dose glu-
tamate or the group I mGluR agonist DHPG significantly
increases the proliferation rates of cultured human neural pro-
genitor cells of neocortical origin [45,46]. In addition, gluta-
mate treatment results in significantly more neurons after
differentiation compared to untreated controls [45]. Moreover,
glutamate has been found to promote both proliferation and
survival of cultured neural precursor cells derived from the rat
forebrain SVZ [13].
In accordance with this, we found that differentiation of our
multi-potent human NSCs in low-dose glutamate-containing
medium resulted in a significantly higher total cell number
compared to cultures grown without glutamate supplements.
Furthermore, the number of ki67-positive cells was signifi-
cantly enhanced for cells exposed to glutamate, providing fur-
ther evidence that glutamate, at certain concentrations,
stimulates cell proliferation.
Interestingly, analysis of LDH in conditioned culture med-
ium collected at days 4 and 12 revealed a significantly lower
concentration of LDH for glutamate-treated cultures compared
to corresponding cultures grown under glutamate-free condi-
tions. This finding suggests that low-dose glutamate has a
positive effect on cell viability, which is consistent with a
study showing decreased apoptosis of human neural progeni-
tors in the presence of the group I mGluR agonist DHPG
[46]. The observed beneficial effect of glutamate on cell sur-
vival may be mediated by mGluR5, as inhibition of mGluR5
has been described to increase apoptosis in neural progenitors
[31,36,46]. However, it could also be explained by the pres-
ence of mGluR3 on the hNS1 cells, as its activation has been
reported to reduce apoptosis in rodent neural precursor cells
[13].
Immunocytochemical analysis of cultures differentiated in
standard growth medium (4 lM glutamate) revealed increased
numbers of b-tub III-positive neurons and a non-significant
tendency for more GFAP-positive astroglial cells. Combined
with our observation of increased proliferative activity, these
data may suggest that low-dose glutamate mainly stimulates
the division of precursor cells with neurogenic potential. This
hypothesis is supported by a previous study on the influence
of glutamate on proliferation and neurogenesis of human neu-
ral progenitor cells derived from the foetal cortex [45].
Effects of glutamate and group I mGluRs on neurogenesis and
gliogenesis.
Previous studies have shown that inhibition of mGluR5 leads
to apoptosis in mouse neuronal progenitor cells undergoing
differentiation into neurons [31,36]. Mice treated with a
selective antagonist of mGluR5, MPEP, show decreased
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Fig. 2. Quantification of human neural stem cells (NSCs) differentiated with or without low-dose glutamate supplements in the culture medium. To
investigate the effects of glutamate-containing supplements in the growth medium, NSCs were differentiated for 12 days in medium with or without
glutamate. When grown in glutamate-containing medium, a significant increase in the numbers of human nuclei (HN)-positive cells (total cells) (A)
and Ki-67-positive proliferative cells (B) was seen. To investigate whether the increased number of HN-positive cells was due to enhanced prolifer-
ation exclusively, lactate dehydrogenase (LDH) measurements were performed in samples of conditioned culture medium collected at days 4 and
12 in vitro (C). At both time-points, significantly less LDH was detected for cultures grown in glutamate-containing medium, compared to cultures
grown in medium without glutamate supplements, suggesting less cell death in cultures exposed to low-dose glutamate. Images of HN-positive and
Ki67-positive cells in differentiating cultures of human NSCs (D). Data are shown as mean  SEM; n = 12–24/condition; 4 independent experi-
ments. ***p < 0.001. Scale bar = 100 lm.
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proliferation of progenitor cells in the hippocampus at early
post-natal stages [47]. Also, the mGluR1 antagonist,
LY367385, has been reported to reduce the number of putative
neuronal progenitors in organotypic hippocampal slice cultures
[48]. In accordance with this, our study showed a significant
reduction in b-tub III-positive cells in cultures exposed to both
the selective mGluR5 antagonist MPEP and the selective
mGluR1 antagonist LY367385. This could indicate that group
I mGluRs are involved in the modulation of neuronal differen-
tiation. However, the observed robust effect was only present
for cultures grown in glutamate-containing medium (fig. 3).
Cultures grown under similar culture conditions but without
glutamate supplements displayed only a tendency towards this
effect (fig. 4). This tendency may reflect that group I mGluRs
are constitutively active on hNS1 cells even without glutamate
stimulation and that further activation with low-dose glutamate
in the medium increases the effects of group I mGluRs. Inter-
estingly, we did, however, not observe an increased number of
b-tubulin III-positive cells when applying the group I mGluR
agonist DHPG. One explanation could be that the effects were
due to the interaction between mGluRs and the ionotropic glu-
tamate receptor NMDA. Other studies have indicated that acti-
vation of group I mGluRs causes internalization and thereby
functional hypoactivity of NMDA receptors [39]. In line with
this hypothesis, it has been shown that activation of NMDA
receptors is important for neurogenesis. Further studies com-
bining pharmacological manipulation of both NMDA and
mGluRs are needed to clarify these mechanisms [49].
Similar mechanisms may explain our observation of a sig-
nificant reduction in the number of GFAP-positive cells
(fig. 3C,D) after exposure to DHPG, which may hint to a
decrease in astrogliogenesis. Activation of mGluR3 has been
shown to impair astrocyte differentiation, but such results have
not been reported previously for group I mGluR agonists [14].
Interestingly, the reduction in GFAP-positive cells was not
present in differentiating hNS1 cells grown under glutamate-
free conditions.
The general lack of effect of group I mGluR ligands on
HSN1 cells differentiated without glutamate might be
explained by the lower proliferation rates and increased cell
death in these cultures blurring any effects. Glutamate signal-
ling through other mGluRs, like mGluR3, might be needed for
the effect of group I mGluR ligands to become apparent. Fur-
ther studies are, however, needed to address this issue.
In conclusion, we have shown that both mGluR1 and
mGluR5 are present on differentiating human NSCs of fore-
brain origin. Furthermore, low-dose glutamate in standard
growth medium increases cell proliferation and reduces cell
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Fig. 3. Quantification of differentiating human neural stem cells (NSCs) cultured in medium with low-dose glutamate and group I metabotropic
glutamate receptor (mGluR) agonists or antagonists. To investigate the effects of glutamate and group I mGluRs on differentiation of human NSCs,
cells were differentiated for 12 days in low-dose glutamate (4 lM)-containing culture medium in the presence or absence of the group I mGluR
agonist DHPG (10 lM) or the selective antagonists LY367385 (mGluR1; 10 lM) and MPEP (mGluR5; 1 lM). Activation of group I mGluRs with
DHPG significantly reduced the number of GFAP-positive astroglial cells, whereas no such significant change was detected for b-tubulin III-posi-
tive neuronal cells. In contrast, selective inhibition of mGluR1 (LY367385) or mGluR5 (MPEP) significantly reduced the number of b-tubulin III-
positive cells (AB) but had no significant effect on GFAP-positive cells (CD). Data are shown as mean  SEM; n = 12–24/condition; 4 indepen-
dent experiments. **p < 0.01, ***p < 0.001. Scale bars = 200 lm.
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death in these cultures. Selective activation of group I mGluRs
in the presence of low-dose glutamate reduces gliogenesis,
whereas selective inhibition of group I mGluRs reduces neuro-
genesis. Our results substantiate the importance of glutamate
signalling in the regulation of NSCs and may as such be
applied to promote proliferation and neuronal differentiation
of human NSCs.
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